Please select the option that best describes you:
Would you offer adjuvant chemotherapy to a woman in her 40's s/p TAHBSO with T2N1 ER+/PR+ breast cancer with oncotype score 21-25?
How much of the benefit of adjuvant chemotherapy do you expect to be due to ovarian function suppression due to the chemotherapy?
Answer from: Medical Oncologist at Academic Institution
Based on RxPONDER trial, post-menopausal women with operable, hormone receptor positive, HER2 negative breast cancer with metastatic disease to 1-3 axillary nodes derived no benefit from chemotherapy if Oncotype dx recurrence score was 25 or less. Analysis by age did not affect this. I would, theref...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
RxPONDER trial overall included 10.3% patients with high grade and 9.2% patients with 3 involved nodes. Premenopausal women with Oncotype Dx Recurrence Score of 16-25 had a small benefit from the addition of chemotherapy but it was unclear if this was due to ovarian suppression effect of chemotherap...